1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Biogen Inc.
  6. News
  7. Summary
    BIIB   US09062X1037

BIOGEN INC.

(BIIB)
  Report
Delayed Nasdaq  -  04:00 2022-06-27 pm EDT
213.57 USD   +0.77%
06/24Biogen Terminates Alzheimer's Drug Aduhelm Study Over Coverage Limits
MT
06/24BIOGEN INC.(NASDAQGS : BIIB) added to Russell Midcap Value Index
CI
06/24BIOGEN INC.(NASDAQGS : BIIB) dropped from Russell Top 200 Value Index
CI
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Tranche Update on Biogen Inc.'s Equity Buyback Plan announced on October 21, 2020.

05/03/2022 | 04:17pm EDT

From January 1, 2022 to March 31, 2022, the company has repurchased 0 shares, representing 0% for $0 million. With this, the company has completed the repurchase of 7,648,931 shares, representing 5.05% for $2,200 million under the buyback announced on October 21, 2020.


© S&P Capital IQ 2022
All news about BIOGEN INC.
06/24Biogen Terminates Alzheimer's Drug Aduhelm Study Over Coverage Limits
MT
06/24BIOGEN INC.(NASDAQGS : BIIB) added to Russell Midcap Value Index
CI
06/24BIOGEN INC.(NASDAQGS : BIIB) dropped from Russell Top 200 Value Index
CI
06/24BIOGEN INC.(NASDAQGS : BIIB) dropped from Russell Top 200 Index
CI
06/24BIOGEN INC.(NASDAQGS : BIIB) added to Russell Midcap Index
CI
06/22Biogen, Happify Health Team Up to Offer Digital Services for Multiple Sclerosis Patient..
MT
06/22Biogen Inc. - European Patent Office Grants Patent Related to TECFIDERA (Dimethyl Fumar..
AQ
06/22Biogen and Happify Health Collaborate to Support Multiple Sclerosis Patients on Digital..
BU
06/22Biogen and Happify Health Collaborates to Support Multiple Sclerosis Patients on Digita..
CI
06/21BIOGEN INC. : Change in Directors or Principal Officers, Submission of Matters to a Vote o..
AQ
More news
Analyst Recommendations on BIOGEN INC.
More recommendations
Financials (USD)
Sales 2022 9 831 M - -
Net income 2022 1 994 M - -
Net cash 2022 60,0 M - -
P/E ratio 2022 15,2x
Yield 2022 -
Capitalization 31 278 M 31 278 M -
EV / Sales 2022 3,18x
EV / Sales 2023 2,98x
Nbr of Employees 9 610
Free-Float 85,5%
Chart BIOGEN INC.
Duration : Period :
Biogen Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends BIOGEN INC.
Short TermMid-TermLong Term
TrendsBullishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 32
Last Close Price 213,57 $
Average target price 242,78 $
Spread / Average Target 13,7%
EPS Revisions
Managers and Directors
Michel Vounatsos Chief Executive Officer & Director
Michael R. McDonnell Chief Financial Officer & Executive Vice President
Stelios Papadopoulos Director
Alphonse Galdes EVP-Pharmaceutical Operations & Technology
Mahalakshmi Radhakrishnan Chief Medical Officer & Group Senior VP
Sector and Competitors
1st jan.Capi. (M$)
BIOGEN INC.-11.67%31 038
CSL LIMITED-6.70%90 814
SAMSUNG BIOLOGICS CO.,LTD.-10.74%45 825
WUXI BIOLOGICS (CAYMAN) INC.-16.59%41 498
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.-12.56%24 084
UCB-19.34%16 152